Borneo Orangutan Survival Foundation, Bogor, Indonesia 16151,
American Association of Zoo Veterinarians, Jacksonville, FL 32218, USA.
J Zoo Wildl Med. 2024 Sep;55(3):769-779. doi: 10.1638/2023-0142.
Orangutan respiratory disease syndrome (ORDS) is a disease unique to orangutans (), characterized by chronic bacterial infection and inflammation of any region or combination of regions of the respiratory tract, including the sinuses, air sacs, cranial bones, airways, and lung parenchyma. Aggressive early intervention during a first episode may prevent progression to chronic disease. However, in the setting of an established chronic disease, intermittent acute exacerbations are associated with worsening symptoms and increased infection and inflammation. ORDS is ultimately fatal due to loss of respiratory function resulting from chronic structural damage. Utilizing potentially lifelong medications to slow the progression of chronic, destructive inflammation in the respiratory tract, chronic treatment is aimed at stabilizing the animals' respiratory function, decreasing the frequency of recurrent exacerbations, and improving their general well-being. Three adult male Bornean orangutans () housed at an orangutan rehabilitation and reintroduction center in Indonesia have long histories of recurrent respiratory disease. Each underwent CT scans confirming ORDS with chronic airway disease prior to initiation of a long-term treatment protocol. Based on data-driven medical management of bronchiectasis in humans, the three orangutans have been treated with long-term combination regimens of oral azithromycin, nebulized salbutamol, and nebulized hypertonic saline. Follow-up CT scans in all three animals at least 1 yr following treatment initiation showed improvements throughout their respiratory tracts. The duration of each exacerbation period decreased, and the orangutans have longer symptom-free periods compared to before the start of treatment. At an average of 5 yr into the long-term treatment protocol, all three orangutans are thriving. Chronic medical management of ORDS modeled after human treatment of bronchiectasis has been efficacious in these three orangutans and encourages further study of this approach.
猩猩呼吸道疾病综合征(ORDS)是一种独特于猩猩的疾病(),其特征为慢性细菌感染和呼吸道任何区域或多个区域的炎症,包括鼻窦、气囊、颅骨、气道和肺实质。在首次发作时进行积极的早期干预可能预防慢性疾病的进展。然而,在已确立的慢性疾病中,间歇性急性恶化与症状恶化以及感染和炎症增加有关。由于慢性结构损伤导致的呼吸功能丧失,ORDS 最终是致命的。利用可能终生使用的药物来减缓呼吸道慢性、破坏性炎症的进展,慢性治疗旨在稳定动物的呼吸功能,减少反复恶化的频率,并改善其整体健康状况。在印度尼西亚的一个猩猩康复和重新引入中心,有三只长期患有复发性呼吸道疾病的成年雄性婆罗洲猩猩()。在开始长期治疗方案之前,每只猩猩都进行了 CT 扫描,以确认患有 ORDS 和慢性气道疾病。根据人类支气管扩张症的基于数据的医疗管理,这三只猩猩接受了长期联合口服阿奇霉素、雾化沙丁胺醇和雾化高渗盐水的治疗方案。在治疗开始后至少 1 年对所有三只猩猩进行的后续 CT 扫描显示,它们的呼吸道均有改善。每次恶化期的持续时间缩短,与治疗开始前相比,猩猩的无症状期更长。在长期治疗方案平均 5 年后,这三只猩猩都茁壮成长。根据人类治疗支气管扩张症的方案对 ORDS 进行的慢性医疗管理在这三只猩猩中是有效的,并鼓励进一步研究这种方法。